Organization
UCB Pharma, N/A, Monheim am Rhein, Germany
3 abstracts
Abstract
ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2Org: UCB Pharma, N/A, Brussels, Belgium, UCB Pharma, N/A, Monheim am Rhein, Germany, UCB Pharma, N/A, Slough, United Kingdom,
Abstract
BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2Org: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, Ruhr-University Bochum, Rheumazentrum Ruhrgebiet Herne, Bochum, Germany, Brigham and Women’s Hospital and Harvard Medical School, Division of Rheumatology, Inflammation and Immunity, Boston, Massachusetts, United States of America, UCB Pharma, N/A, Brussels, Belgium,
Abstract
BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIESOrg: Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet Herne, Bochum, Germany, Oregon Health & Science University, Arthritis and Rheumatic Diseases, Portland, United States of America, Leiden University Medical Center (LUMC), Department of Rheumatology, Leiden, Netherlands, University Hospitals, Case Western Reserve University, Cleveland, United States of America, University of Alberta, Department of Medicine, Edmonton, Canada,